Influensa-behandlinger

Influenza treatments in Europe

Influenza is a highly contagious acute respiratory infection caused by influenza A and B viruses. It represents a significant annual public health challenge across Europe, with seasonal epidemics causing millions of illness episodes and thousands of deaths each year. The European Centre for Disease Prevention and Control (ECDC) estimates that influenza is responsible for approximately 40,000 excess deaths per year in the EU, the vast majority occurring in vulnerable and elderly populations.

Most healthy adults with influenza experience a self-limiting illness characterised by sudden onset of fever, myalgia (muscle aches), headache, dry cough, sore throat, and fatigue. Symptoms typically resolve within 5–8 days, though fatigue and cough may persist longer. The high contagiousness of influenza — spread via respiratory droplets and contact with contaminated surfaces — means that seasonal epidemics can propagate rapidly through communities.

For healthy adults with uncomplicated influenza, symptomatic management with rest, adequate fluid intake, and over-the-counter analgesics and antipyretics is often sufficient. However, for patients in high-risk groups or those presenting with more severe illness, antiviral medications can significantly reduce the duration and severity of symptoms, lower the risk of complications such as secondary bacterial pneumonia, and decrease the risk of hospitalisation.

Antiviral medications work by interfering with the replication or spread of the influenza virus. They do not treat bacterial infections and are not effective against the common cold or other respiratory viruses. Their benefit is critically time-dependent — treatment is most effective when initiated within 48 hours of symptom onset — which is why rapid access to medical assessment is clinically valuable.

Available treatments

The following antiviral medications for influenza may be available through EU-registered doctors. This comparison is provided for informational purposes only.

Key distinctions:

• Oseltamivir (Tamiflu): The most widely prescribed influenza antiviral in Europe. Oral administration and good tolerability make it practical for outpatient use. A paediatric liquid suspension is also available. Generic oseltamivir is available in many EU countries.
• Zanamivir: Administered via inhalation using a Diskhaler device. An alternative for patients who cannot tolerate oral oseltamivir, but not suitable for patients with underlying respiratory conditions such as asthma or COPD due to risk of bronchospasm.
• Baloxavir (Xofluza): A newer antiviral with a novel mechanism, taken as a single oral dose. Approved by the EMA. May be preferred by patients for whom a full 5-day course represents an adherence challenge. Clinical data show comparable efficacy to oseltamivir for uncomplicated influenza.

How to get influenza treatment online

Prescrivia operates as a technology intermediary. We do not prescribe medications, employ doctors, or sell medicines. Our platform connects patients across Europe with independent EU-registered doctors and licensed pharmacies.

The process:

1. Complete a health assessment — Answer a structured set of medical questions covering your symptoms, time of onset, medical history (particularly high-risk conditions), current medications, and any known exposure history. Speed of assessment is important given the 48-hour treatment window.

2. Independent doctor review — An independent EU-registered doctor reviews your assessment. If antiviral treatment is clinically appropriate based on your risk profile and symptom timing, the doctor may issue a prescription. If your symptoms suggest a different diagnosis or require urgent in-person care, the doctor will advise accordingly.

3. Pharmacy fulfilment — If a prescription is issued, it is passed to a licensed EU pharmacy partner. The medication is dispensed and delivered to your address as quickly as possible.

Important: Prescrivia does not guarantee that a prescription will be issued. Prescribing decisions are made entirely by independent medical professionals. Given the time-sensitive nature of antiviral treatment, same-day or next-day delivery options may be relevant — check availability in your country at checkout.

How we compare

Note: Influenza presenting with difficulty breathing, chest pain, confusion, severe or persistent vomiting, or symptoms of deterioration after initial improvement warrants immediate in-person emergency evaluation. Online assessment is appropriate for adults with uncomplicated influenza symptoms whose condition is stable and who can safely await assessment and delivery.

Sources

Medical information on this page is based on the following sources:

• European Medicines Agency (EMA). Tamiflu (oseltamivir) — Summary of Product Characteristics. Available at: ema.europa.eu
• European Centre for Disease Prevention and Control (ECDC). Influenza — annual epidemiological report. ecdc.europa.eu
• World Health Organization (WHO). Influenza (seasonal) — Key facts. who.int

This content is reviewed periodically to reflect updated clinical guidance. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.